There was a study performed on military patients that have been given a number of several medications this kind of as amphetamine, Provigil drug along with there was furthermore a manage placebo collection. These people had to stay 4 days without sleep, The finest outcomes are already accomplished with people that widely used Provigil generic, as well as there continues to be notice an improvement in response time frame, recollection features and mood. An additional advantage of Provigil generic is that it has a lot much less negative effects, along with considered to become a safe medicine to consider.

Patients with this disorder experience an uncontrollable need for sleep, which can happen a number of times during the day.

People with that disorder usually fall asleep on a spot, and can remain asleep for an extended period of time. In some cases these sleepiness periods can last more than an hour.

These sleepiness periods can happen any minute,that is why Narcolepsy is potentially dangerous, if this person drives a car or performs any other dangerous activity.

The symptoms, common for narcolepsy are :excessive sleepiness, cataplexy ( loss of muscle tone), hallucinations and paralysis.

Narcolepsy affects about 1 in 200o people, and it can affect anybody, any age, race or social group.

The medication prescribed for this disorder is Provigil, which helps to reduce excessive sleepiness.

Because of the number of potential side effects which can happen while taking Provigil, it’s recommended to use this medicine with caution.

In the last few years because of the economic growth we are developed into so-called “24 hour/day society”.  The latest survey says that about 20% pf people are doing alternating shifts. But the recent trends prove that the number of these people, especially in some areas of trade, is in rise.

People doing shift work tend to take more sick leave and also have the increased risk of developing some diseases such as ulcer or heart disease. Women working night shifts are more likely to develop problems with periods or difficulty with pregnancy.

Unfortunately sleep disorders do not only effect the night hours, they also have a major impact on the day activities as well, such as our mental well-being, the level of stress, our productivity, and the safety.

Such symptoms can seriously impair a person’s performance and ability to function, in part because of the reduction in sleep quality and quantity, and because performance and alertness rhythms will take several days to resynchronise. In the long-term (eg, after 4 years), chronic disruption of circadian rhythms from regular transmeridian travel might result in cognitive deficits (decreased short-term memory, slower reaction time) and changed physiological parameters (such as cortisol concentrations).

Because of their rapidly changing and conflicting light-dark exposure and activity-rest behaviour, shiftworkers can have symptoms similar to those of jetlag. Although travellers normally adapt to the new time zone, shift-workers usually live out of phase with local time cues.

Shift-work schedules are generally classified in terms of the speed (rapid or slow) and direction (forward or backward) of rotation. The issue of which schedules are preferable from the perspective of sleep and biological rhythm research is contentious.(1) On the one hand, in rapidly rotating schedules, which incidentally are rarely used in North America, the biological clock maintains a normal phase and workers are thus able to continue their conventional activities during off-duty days without symptoms of internal desynchrony. However, the problem with such schedules is that shifts can, and often do, coincide with the time of day when the biological drive for sleepiness is high and performance is low. By contrast, a slow rotation schedule is conducive to circadian adaptation. During days off duty, workers typically revert to the conventional day-active pattern. In Antarctica and in one North Sea oil rig shift schedule (figure 3) complete adaptation is found, but such situations are rare.(29,30) In the offshore situation, many more complications are seen in sleep and performance in the rollover shift than with 2 weeks of night shift.(31) The theoretical notion of directional asymmetry in circadian adaptation to rotating shift schedules is based on the same principles as for time zone travel; forward (clockwise) shift rotation would result in more rapid adaptation than backward rotation. To date, however, field studies have failed to conclusively show that backward rotation is more detrimental than forward.(32)

In addition to disruption of sleep, abrupt changes in time cues might have negative effects on other physiological systems. Compared with the effects of sleep, few studies have examined the effects of shiftwork on cardiovascular, digestive, immune, and reproductive systems, all of which are rhythmic in nature.(26) Epidemiological studies are problematic; we know that people who are intolerant to shiftwork tend to select themselves out of such occupations. A review of studies(34) that investigated shift work and risk of cardiovascular disease claimed that on balance, shift-workers have a 40% increase in risk. Investigators have shown that meals taken during biological night (or during an unadapted night shift) lead to higher plasma triacylglycerol concentrations (an independent risk factor for heart disease) than identical meals taken during the day, which might in part explain the increased occurrence of cardiovascular disease among shiftworkers.(35,36) Glucose tolerance is also known to deteriorate in the evening,(37) and there is evidence that increased peripheral insulin resistance might contribute to this effect.(6) Resistance to insulin is a putative risk factor for cardiovascular disease and type 2 diabetes mellitus, and again, this could explain the raised incidence of disease among shiftworkers.

Strategies have been developed to enhance circadian adaptation to shift-work schedules and time zone changes. Factors that promote sleep hygiene are advised, such as adequate sleep, sleep in a quiet and dark environment, control of the use of caffeine and alcohol, and timing sleep (with or without the use of hypnotic agents) to the desired sleep time relative to the new time zone or shift schedule. As described earlier, exposure to light can phase shift circadian rhythms. Therefore, scheduled bright light exposure and avoidance of light (possibly by use of dark goggles) might be useful in accelerating adaptation.(38) Most field studies and laboratory-simulated phase-shift studies report that correctly timed administration of the hormone melatonin is also able to moderately shorten the time taken for circadian adaptation.(26) However, there is little evidence for optimum dose or formulation, and there is no information on long-term safety. Further research is needed to examine how combined administration of bright light and melatonin could be used to develop effective, reliable, and practical treatment strategies.

It is not always desirable to adapt the circadian system to new shift schedules, for example in rapidly rotating shifts, because sleep and activity on rest days will be compromised. Similarly, when travel to a new time zone is for a short time (eg, 1 or 2 days), circadian re-adaptation might not be worthwhile. In such cases, short-term strategies can be used to maintain alertness and performance, especially during early morning hours, and to improve sleep, without shifting the biological clock.

The method developed by Dr. Roerig and colleagues uses brief placebo-controlled trials with normal volunteers to determine whether a prospective treatment drug deserves study in clinical trials.

The process starts with a brief trial to show that the main treatment agent will produce the target adverse effect in normal volunteers; it is followed by a short placebo-controlled study to see whether adding the candidate drug reduces the adverse effect enough in normal volunteers to signal that the test drug is likely to work and deserves further study.

“If you look at studies of atypical antipsychotic agents tested . . . for efficacy, olanzapine looks a little better than some of the other drugs, but clinicians worry about the associated risk of weight gain. We thought it would be useful to try to solve that problem,” Dr. Roerig said.

The researchers enrolled 50 normal volunteers in the study and randomized them to either 3 weeks of olanzapine plus placebo or 3 weeks of olanzapine plus Provigil titrated to 200 mg/day. The primary outcome variable was a change in body-mass index (BMI) over the 3 weeks of the trial.

Both groups had increases in BMI, but Dr. Roerig reported that analysis of covariance controlling for baseline BMI showed a significantly lower weight gain in the olanzapine/Provigil group (0.47 vs 0.89 kg/m2; P < .05).

“The results of this trial should not be extrapolated to clinical practice at this time,” Dr. Roerig warned. “But the data do support further clinical studies to determine if the effect of Provigil can be demonstrated over a longer period of time, and in relevant patient populations.”

Guy Faulkner, PhD, associate professor at the University of Toronto’s Faculty of Physical Education and Health, in Ontario, and lead author of a recent Cochrane review of interventions to reduce weight gain in schizophrenia, raised a different concern (Cochrane Database Syst Rev. 2007;1:CD005148).

“Many of these patients are already on elaborate cocktails of drugs, and this would add yet another drug to the mix. It would also increase the risk of drug interactions, many of which we do not yet know much about. The difference in weight gain in this study was small, and I am not sure it justifies further exploration,” Dr. Faulkner told Medscape Psychiatry. “The greater focus should probably be on developing antipsychotics that are less likely to cause weight gain.”

Dr. Faulkner reiterated the conclusion from his Cochrane review study: pharmacologic intervention should only be tried if behavioral and lifestyle interventions have failed to prevent or reverse weight gain in patients taking antipsychotics.

“The range of steps when beginning a patient on 1 of these drugs should include proper screening, warning the patient about this potential side effect, referring the patient for diet and physical-activity counseling where available, and monitoring the patient’s weight regularly.

“Counseling should consider the patient’s activity level and appetite, as well as the patient’s insight into the effects of their activity level and of what they are eating. If there is a big weight increase, consider switching the patient to a different antipsychotic agent, since there is considerable heterogeneity in individual responses,” Dr. Faulkner said.

Continuous measures of electroencephalogram (EEG) sleep-wakefulness, locomotor activity (LMA) and body temperature (Tb) were obtained from adult male Wistar rats 3 days before and after treatment with Provigil (30, 100 and 300 mg/kg i.p.), 0.25% methylcellulose (vehicle) or METH (0.5 and 1.0 mg/kg i.p.). Individually housed rats in a 24-h light-dark cycle (LD 12:12) were treated 5 h after lights-on (CT-5).

LMA and Tb were monitored via intraperitoneal telemetry. Sleep-wake stages and LMA were recorded every 10 s, Tb every minute. During the first 3 h post-treatment, Provigil and METH significantly and dose-dependently increased EEG wake time (P < .01 for 30 mg/kg Provigil, all other P < .0001) and wake episode duration.

Although the cumulative increases in wakefulness were statistically equivalent, METH, but not Provigil, produced subsequent rebound hypersomnolence.

At these equipotent wake-promoting doses, Provigil produced the same total amount of REM sleep inhibition but during a longer time than METH. Provigil also increased LMA amount (counts/h, P < .001) and LMA intensity (counts/min awake, P < .001) less than METH. Both rebound hypersomnolence and increased LMA intensity, which are undesirable features in wake-promoting drugs, were not observed after Provigil treatment, and thus further differentiated Provigil from amphetamine-like stimulants.

The level of arousal is controlled by an intricate interplay between distinct wakefulness – and sleep-promoting nuclei situated in the hypothalamus and brainstem and the interconnections between the nuclei and the neurotransmitters involved have been mapped.

Wakefulness-promoting nuclei include the orexinergic lateral hypothalamic/perifornical area, the histaminergic tuberomammillary nucleus, the cholinergic pedunculopontine tegmental nucleus, the noradrenergic locus coeruleus, the 5-hydroxytryptaminergic raphe nuclei and possibly the dopaminergic ventral tegmental area.

The major sleep-promoting nucleus is the GABAergic ventrolateral preoptic nucleus of the hypothalamus. Currently available and future drugs exert their therapeutic effects in the three major classes of sleep disorder (insomnia, hypersomnia, parasomnia) by modifying neurotransmission at distinct sites within the arousal-controlling neuronal network. This enables classification of therapeutic drugs for sleep disorders on the basis of their modes of action: drugs that interact with the GABAergic sleep-promoting system, drugs that interact with different wakefulness-promoting systems and drugs that modulate the level of arousal by mechanisms that do not initially involve the basic network (e.g. melatonin, adenosine).

The development of novel therapeutic drugs for sleep disorders is based on the synthesis of molecular/cellular mechanisms and the sites of action within the arousal-controlling neuronal network.

This article provides recommendations for the diagnosis and management of narcolepsy. The cataplexy associated with narcolepsy can be managed with tricyclic antidepressants.

The excessive sleepiness is managed with stimulants but newer agents, such as Provigil, which will be marketed as Provigil, and selegiline hydrochloride, with fewer adverse effects and less abuse potential, may offer means of promoting daytime wakefulness.

Groups such as the National Sleep Foundation, Washington, DC, and the Narcolepsy Network, Cincinnati, Ohio, can provide patients with needed support and information.